Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.

被引：1
|
作者：
Vire, Berengere [1 ]
Perry, Justin S. A. [2 ]
Lee, Elinor [1 ]
Stennett, Lawrence S. [1 ]
Samsel, Leigh [3 ]
McCoy, Philip [3 ]
Wilson, Wyndham H. [4 ]
Bielekova, Bibiana [2 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
[3] NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA
[4] NCI, CCR, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.1610.1610
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：643 / 644
页数：2
相关论文
共 50 条
  • [31] Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression
    Yu-Yan Hwang
    Kai Y. Wong
    Rock Y. Y. Leung
    Simon H. M. Wong
    See-Ching Chan
    Gopesh Srivastava
    Wing Y. Au
    Annals of Hematology, 2010, 89 : 97 - 99
  • [32] Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
    Carla Serra-Peinado
    Judith Grau-Expósito
    Laura Luque-Ballesteros
    Antonio Astorga-Gamaza
    Jordi Navarro
    Jenny Gallego-Rodriguez
    Mario Martin
    Adrià Curran
    Joaquin Burgos
    Esteban Ribera
    Berta Raventós
    Rein Willekens
    Ariadna Torrella
    Bibiana Planas
    Rosa Badía
    Felipe Garcia
    Josep Castellví
    Meritxell Genescà
    Vicenç Falcó
    Maria J. Buzon
    Nature Communications, 10
  • [33] Influence of cytokines on CD20 expression and Rituximab-induced CDC on MC/CAR myeloma cells
    Umeda, M
    Kuraishi, Y
    Nakai, S
    Furukawa, K
    Akahane, S
    Tsuru, H
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 99P - 99P
  • [34] Upregulation of CD20 on human acute lymphoblastic leukemia cells by IL-4 and CpG motif containing oligonucleotides increases susceptibility to rituximab.
    Nijmeijer, Bart
    Van Schie, Marianke L. J.
    Willemze, Roelof
    Falkenburg, J. H. Frederik
    BLOOD, 2006, 108 (11) : 533A - 533A
  • [35] Phase II study of single agent rituximab in previously treated multiple myeloma patients: Patients with CD20+BM plasma cells may derive benefit from rituximab.
    Treon, SP
    Belch, AR
    Grossbard, ML
    Schlossman, RL
    Ellman, L
    Harmon, D
    Doss, DS
    Preffer, FI
    Kelliher, AS
    Pilarski, LM
    Anderson, KC
    BLOOD, 2000, 96 (11) : 164A - 164A
  • [36] Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression
    Hwang, Yu-Yan
    Wong, Kai Y.
    Leung, Rock Y. Y.
    Wong, Simon H. M.
    Chan, See-Ching
    Srivastava, Gopesh
    Au, Wing Y.
    ANNALS OF HEMATOLOGY, 2010, 89 (01) : 97 - 99
  • [37] Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
    Aue, Georg
    Lindorfer, Margaret A.
    Beum, Paul V.
    Pawluczkowycz, Andrew W.
    Vire, Berengere
    Hughes, Thomas
    Taylor, Ronald P.
    Wiestner, Adrian
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 329 - 332
  • [38] CD20 EXPRESSION IN THE TRANSPLANTED KIDNEY OF PATIENTS WITH GRAFT LOSS AND TRANSIENT ALLOGRAFT DYSFUNCTION
    Han, Yong
    Shi, Bingyi
    Cai, Ming
    Xu, Xiaoguang
    Xu, Liang
    Wang, Qiang
    Zhou, Wenqiang
    Xiao, Li
    JOURNAL OF MEDICAL BIOCHEMISTRY, 2012, 31 (01) : 1 - 5
  • [39] Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti- CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
    Wada, Naoki
    Kohara, Masaharu
    Ogawa, Hiroyasu
    Sugiyama, Haruo
    Fukuhara, Shirou
    Tatsumi, Yoichi
    Kanamaru, Akihisa
    Hino, Masayuki
    Kanakura, Yuzuru
    Morii, Eiichi
    Aozasa, Katsuyuki
    CASE REPORTS IN ONCOLOGY, 2009, 2 (03): : 194 - 201
  • [40] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    Freeman, C. L.
    Dixon, M.
    Houghton, R.
    Kreuzer, K-A
    Fingerle-Rowson, G.
    Herling, M.
    Humphrey, K.
    Boettcher, S.
    de Costa, C. S.
    Iglesias, V.
    Stilgenbauer, S.
    Gribben, J.
    Hallek, M.
    Goede, V.
    LEUKEMIA, 2016, 30 (08) : 1763 - 1766
12345